Edesa Biotech Inc (EDSA)
2.16
+0.05
(+2.37%)
USD |
NASDAQ |
Nov 22, 13:33
Edesa Biotech Net Income (Quarterly): -1.668M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -1.668M |
| March 31, 2024 | -1.861M |
| December 31, 2023 | -1.678M |
| September 30, 2023 | -1.720M |
| June 30, 2023 | -1.985M |
| March 31, 2023 | -2.334M |
| December 31, 2022 | -2.335M |
| September 30, 2022 | -2.814M |
| June 30, 2022 | -5.787M |
| March 31, 2022 | -4.569M |
| December 31, 2021 | -4.379M |
| September 30, 2021 | -3.686M |
| June 30, 2021 | -4.760M |
| March 31, 2021 | -2.26M |
| December 31, 2020 | -2.638M |
| September 30, 2020 | -2.014M |
| June 30, 2020 | -1.766M |
| March 31, 2020 | -1.490M |
| December 31, 2019 | -1.094M |
| September 30, 2019 | -0.9539M |
| June 30, 2019 | -1.294M |
| March 31, 2019 | -1.656M |
| December 31, 2018 | -1.406M |
| September 30, 2018 | -1.129M |
| June 30, 2018 | -1.157M |
| Date | Value |
|---|---|
| March 31, 2018 | -1.352M |
| December 31, 2017 | -1.401M |
| September 30, 2017 | -1.221M |
| June 30, 2017 | -1.220M |
| March 31, 2017 | -1.104M |
| December 31, 2016 | -1.486M |
| September 30, 2016 | -1.341M |
| June 30, 2016 | -1.194M |
| March 31, 2016 | -0.861M |
| December 31, 2015 | -1.630M |
| September 30, 2015 | -1.537M |
| June 30, 2015 | 0.464M |
| March 31, 2015 | -0.4262M |
| December 31, 2014 | -1.344M |
| August 31, 2014 | -4.635M |
| May 31, 2014 | 1.813M |
| February 28, 2014 | -0.238M |
| November 30, 2013 | -5.380M |
| August 31, 2013 | -8.914M |
| May 31, 2013 | -1.172M |
| February 28, 2013 | -3.644M |
| November 30, 2012 | -0.7659M |
| August 31, 2012 | -2.044M |
| May 31, 2012 | -1.405M |
| February 29, 2012 | -1.124M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-5.787M
Minimum
Jun 2022
-1.094M
Maximum
Dec 2019
-2.676M
Average
-2.26M
Median
Mar 2021
Net Income (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 14.35M |
| Lexaria Bioscience Corp | -1.782M |
| Xenon Pharmaceuticals Inc | -62.79M |
| ESSA Pharma Inc | -7.234M |
| ImmunoPrecise Antibodies Ltd | -2.920M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.696M |
| EPS Diluted (Quarterly) | -0.52 |
| Enterprise Value | 4.811M |
| Earnings Yield | -101.8% |
| Normalized Earnings Yield | -239.82 |